Conditions · Pancreatic cancer
Pancreatic cancer — clinical trials in Spain
30 open options
- TRIALPHASE4RECRUITING
Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.
creon 35.000 Ph.U (R) · Best Standarard of Care — 4 sites
- TRIALPHASE2RECRUITING
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Autogene cevumeran · Atezolizumab · mFOLFIRINOX — 89 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BNT329 · CA19-9-targeting monoclonal antibody — 16 sites
- TRIALPHASE2RECRUITING
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AZD0901 · 5-Fluorouracil · Leucovorin — 52 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Elironrasib · Daraxonrasib — 55 sites
- TRIALPHASE1RECRUITING
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
DSB2455 — 18 sites
- TRIALPHASE2NOT_YET_RECRUITING
A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.
Gemcitabine (1000 mg/m2) · Nab-paclitaxel (Abraxane) · NLM-001 — 6 sites
- TRIALPHASE1 / PHASE2RECRUITING
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
TTFields concomitant with modFOLFIRINOX — 5 sites
- TRIALPHASE3RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RYZ101 · Everolimus · Sunitinib — 54 sites
- TRIALPHASE1RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 · Pembrolizumab · Panitumumab — 39 sites
- TRIALNARECRUITING
The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy
HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy — 1 site
- TRIALPHASE3RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
daraxonrasib — 66 sites
- TRIALPHASE1RECRUITING
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
LY4170156 · bevacizumab · carboplatin — 23 sites
- TRIALNARECRUITING
Robotic vs Open Pancreatoduodenectomy
Robotic pancreatoduodenectomy · open pancreatoduodenectomy — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
SBP-101 · Nab-paclitaxel · Gemcitabine — 93 sites
- TRIALPHASE1RECRUITING
A Study of PHN-012 in Patients With Advanced Solid Tumors
PHN-012 — 26 sites
- TRIALPHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
LY4052031 — 39 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab · placebo — 220 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734 · Cetuximab · Retifanlimab — 34 sites
- TRIALNANOT_YET_RECRUITING
Impact of Hypertrophy-oriented Resistance Training on Muscle Mass and Quality of Life in Patients With Unresectable Pancreatic Cancer
supervised, hypertrophy-oriented strength training program — 1 site
- TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
- TRIALPHASE2RECRUITING
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
BAY2927088 — 54 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer
VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) · Nab-paclitaxel + Gemcitabine — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
INCB161734 · Placebo · Investigator's choice of chemotherapy — 219 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
ART0380 · Gemcitabine · Irinotecan — 82 sites
- TRIALPHASE1RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
PF-08046050 · bevacizumab · 5-Fluorouracil (5-FU) — 48 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Sacituzumab tirumotecan · Fluorouracil (5-FU) · Leucovorin (LV) or levoleucovorin — 55 sites
- TRIALPHASE1RECRUITING
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
PF-08046876 — 30 sites
- TRIALPHASE1 / PHASE2RECRUITING
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
CP-506 · Carboplatin · Immune checkpoint inhibitor — 5 sites
- TRIALPHASE2RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
HER3-DXd — 86 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.